Article Details

AstraZeneca and Daiichi Sankyo's Enhertu becomes first HER2-directed therapy for NSCLC

Retrieved on: 2022-08-12 15:52:06

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca and Daiichi Sankyo's Enhertu becomes first HER2-directed therapy for NSCLC. View article details on HISWAI: https://www.pharmalive.com/astrazeneca-and-daiichi-sankyos-enhertu-becomes-first-her2-directed-therapy-for-nsclc/

Excerpt

AstraZeneca and Daiichi Sankyo noted that additional clinical data may be required by the FDA from a confirmatory trial due to the parameters of ...

Article found on: www.pharmalive.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up